SUMMARY -Due to progressive dyspnea, a male patient aged 59 underwent medical examination in 2003 in a local hospital. Neck ultrasound and fine-needle aspiration biopsy (FNAB) of a suspect lesion in the thyroid gland revealed the presence of a malignant neoplasm, i.e. mesenchymal tumor. Immunocytochemistry for epithelial membrane antigen, chromogranin A and leukocyte common antigen (CD45) was negative, while vimentin and S-100 were positive. The patient was referred to a university hospital center, where further oncologic work-up was done. Neck ultrasound revealed a tumor in the left lobe of the thyroid, with extension to the aortic arch. After repeated FNAB, cytologic diagnosis of primary thyroid fibrosarcoma was established. Due to the locally advanced and consequently inoperable disease, primary radiotherapy to the neck region (64 Gy in 32 fractions) was applied, followed by 6 cycles of chemotherapy with doxorubicin. After completion of therapy, computed tomography scan demonstrated significant regression of primary disease, but it was still not amenable to surgical treatment. Thus, the decision of the oncology board was active surveillance of the patient. During 9-year follow up, no signs of progression or activity of the disease were found.
Introduction
Fibrosarcoma is a malignant tumor of mesenchymal cell origin derived from fibrous connective tissue, composed of malignant fibroblasts in a collagen background. It is a rare tumor, accounting for 1%-3% of all human sarcomas. Nowadays, it is diagnosed less frequently, since it can be more reliably distinguished histopathologically from similar lesions, such as desmoid tumors and malignant fibrous histiocytoma. Primary fibrosarcoma of thyroid gland is exceptionally rare 1 , and only few case reports of this type of tumor have been reported in the world [2] [3] [4] [5] [6] [7] [8] . Until now, there are no known etiologic factors associated with the disease. Most commonly, deep soft tissue of lower extremities (especially thighs and knees) is affected, but it can also develop in upper extremities, chest, head, neck, as well as in other parts of the body (breast, lung and central nervous system). Soft tissue fibrosarcoma usually affects patients of a wider age spectrum than fibrosarcoma of the bone does, and can occur at any age, with the peak incidence between age 30 and 55. Although it can develop in the areas of previously damaged skin (burns, trauma, chemicals, radiotherapy, etc.), it usually arises from unchanged normal tissue (de novo). The tumor may present different degrees of differentiation: low grade (differentiated), intermediate malignancy and high malignancy (anaplastic). It is generally a large, painless mass deep to fascia and 
Case Report
A 59-year-old male patient was hospitalized due to progressive dyspnea in a local hospital in March 2003, where thyroid ultrasound (US) and subsequent fine-needle aspiration biopsy (FNAB) showed the existence of a malignant neoplasm, i.e. mesenchymal tumor. Immunocytochemistry for epithelial membrane antigen, chromogranin A and leukocyte common antigen (CD45) was negative, while vimentin and S-100 were positive.
In July 2003, the patient was referred to a university hospital center. Physical examination revealed a large palpable mass in the left lobe of the thyroid. To evaluate the stage of the disease, neck ultrasound (US) and chest and neck computed tomography (CT) were done. A locally advanced process was found in the left lobe of the thyroid, extending up to the aortic arch, 3.5 cm above the tracheal bifurcation. The described tumor measured 82 mm in cranio-caudal and 76 mm in latero-lateral diameter (Fig. 1) . The patient underwent US-guided FNAB. Cytologic smears were air dried and May-Grünwald-Giemsa stained. The smears were normocellular and consisted of loose bundles of spindle-shaped cells with fusiform nuclei and elongated, poorly delimited cytoplasm (Fig. 2) . On the basis of morphological and previously known immunocytochemistry features, FNAB diagnosis of fibrosarcoma was confirmed. Based on the opinions of an otorhinolaryngologist and a thoracic surgeon, the disease was inoperable, and the conclusion of the oncology board was to treat the patient with sequential radiochemotherapy. Total tumor dose of 64 Gy in 32 fractions was applied, with a short break due to the development of grade 3 radiodermatitis. After radiotherapy, 6 cycles of chemotherapy with doxorubicin were applied (after the first cycle, the dose was After completion of chemotherapy, significant regression of the expansive lesion in the left lobe of the thyroid was recorded (the tumor measured 4.2 cm on CT scan), with no evidence of enlarged lymph nodes in the mediastinum (Fig. 3) . However, it was still not amenable to surgical treatment due to the proximity of vital structures. Follow up head and neck CT in October 2005 demonstrated an inhomogeneous infiltrative process located in the left paratracheal and retrotracheal space. The tumor spread from the lower half of the left lobe of the thyroid, with cranio-caudal diameter of about 6 cm, antero-posterior 3 -3.5 cm and latero-lateral up to 4 cm. Part of the esophagus was surrounded by the tumor, and the trachea was shifted to the right, with narrowed lumen in latero-lateral direction. Last CT scan in September 2009 demonstrated no signs of disease progression. The process was still located in the base of the neck and trachea, with the largest diameter of 5.5 cm, reaching out to the edges of the vertebrae.
The patient underwent regular follow ups, the last one in October 2014, and until now no signs of progression or dissemination of the disease were recorded, so there was no indication for further oncologic treatment. The patient felt subjectively well throughout the follow up period and reported no symptoms other than mild swallowing difficulties.
Discussion
Besides fibrosarcoma, all other types of sarcoma can be found in the thyroid gland, including liposarcoma, leiomyosarcoma, chondrosarcoma, osteosarcoma and malignant schwannoma 1 . They all are extremely rare and are only sporadically reported 10, 11 . Because of its extremely rare incidence, fibrosarcoma has not yet been included in the TNM classification of thyroid tumors.
Since radiological signs are not specific, the only way to diagnose primary thyroid fibrosarcoma is with the help of a cytologist or pathologist. It has to be noted that cytologic finding may sometimes be inconclusive, and can fail to make the correct diagnosis. In that case, histopathologic diagnosis by taking the sample of the tumor tissue is mandatory. Our patient underwent FNAB twice, first at a local hospital, where the cytologist reported mesenchymal tumor, but no further analysis could be done to determine the tumor subtype. Some recent studies have shown that repeat thyroid FNAB is useful in most cases of primary indeterminate FNAB findings 12 . Thus, FNAB was later repeated during work-up in our department, when upon morphological and previously known immunocytochemistry characteristics, the diagnosis of fibrosarcoma was made. Since the result was clear, histopathologic confirmation of the diagnosis was not required.
The natural course of the disease is not characteristic either, with some authors reporting slow-growing tumors, and other rapid course of the disease 4 . The patient underwent primary radiotherapy and chemotherapy, since the locally advanced disease was found during work-up. After primary therapy, the tumor was still not amenable to surgical resection and the patient was followed-up regularly every 6 months. No signs of progression of the disease or of distant metastasis have been found to date, so it is evident that our patient is fortunately in the group of slow-growing thyroid fibrosarcoma. Considering the fact that the tumor was inoperable initially, and even after radio-and chemotherapy, and later on no progression of the disease was found, it is clear that thyroid fibrosarcomas are a very unpredictable group of tumors, and it is still (due to Fibrosarcoma of the thyroid gland a small number of reported cases) not possible to describe precisely their behavior and prognosis. Despite the fact that in our patient, no activity of the disease was found in the last 9 years, the decision of our oncology board was to continue regular follow up. Thyroid function was assessed at every patient visit; tests included thyroid-stimulating hormone, thyroxine/free thyroxine and triiodothyronine/free triiodothyronine. Despite the large tumor mass that caused atrophic changes by tissue pressure, the patient has remained euthyroid to date.
Standard guidelines for the treatment of thyroid fibrosarcoma are, considering the small number of reported cases, not available. General agreement is that surgical treatment with adequate margins is the mainstay of treatment. The role of radiotherapy and chemotherapy is not clear. Radiotherapy is usually applied postoperatively in case of inadequate surgical resection, while chemotherapy is an option in highgrade tumors (as adjuvant therapy), as well as for inoperable (as it was in our case) or metastatic disease.
